Objective: To evaluate the effects of cervical single-door laminoplasty that preserving insertion of semi-spinus muscle on C ₂ vertebral body for treating cervical spondylotic melopathy. Methods: 60 patients with cervical spondylotic myelopathy were divided into group A and group B according to different surgical methods, 30 patients in each group. The patients in group A received C _3-7 cervical single-door laminoplasty, the patients in group B received C _4-7 cervical single-door laminoplasty. The JOA scores of patients before and at the last follow-up were analyzed, and the improvement rate of neurological function was calculated; The cervical curvature (Cobb angle) of the two groups before and at the last follow-up were compared; And the incidence rate of postoperative axial symptoms, C ₅ nerve root paralysis were recorded. Results: At the last follow-up, the cervical curvature of patients in 2 groups was obviously lost compared with that before operation (P<0.05); At the last follow-up, the Cobb angle of patients in group A was obviously lower than group B (P<0.05). There was no significant difference in JOA score before and after operation, neurological improvement rate and incidence rate of complications between group A and group B (P>0.05). The JOA score of patients in 2 groups after operation were all obviously higher than than before operation (P>0.05). Conclusions: Treating cervical spondylotic myelopathy with C _3-7 and C _4-7 cervical single door laminoplasty all can get significant recovery of neurological function. While the cervical single-door laminoplasty with preservation of hemi-spinus muscles insertion on C ₂ vertebral body not only can maintain the cervical curvature, but also can decrease the incidence rate of axial symptoms.

Objective: To compare the clinical effects and safety pemetrexed combined with platinum and other platinum duplex regimens for treating non-drive gene positive advanced lung adenocarcinoma. Methods: 120 cases of non-drive gene positive advanced lung adenocarcinoma patients were divided into experimental group (n=55) and control group (n=65) according to treatment. The patients in experimetal group were treated with pemetrexed combined with platinum regimens, while the patients in control group were treated with TP(taxol+cisplatin) / DP(docetaxel+cisplatin) / GP(gemcitabine+cisplatin) chemotherapy regimens. The curative effects and safety of patients in 2 groups were evaluated after 4 treatment cycles. Results: The overall response rate (ORR), disease control rate (DCR), overall survival (OS), 1 year survival rate of patients in experimental group were obviously higher than control group (P<0.05). The incidence rate of thrombocytopenia, leukopenia and anemia of patients in experimental group were obviously lower than control group (P<0.05). Conclusions: Compared with TP/DP/GP regimen, treating non-drive gene positive advanced lung adenocarcinoma with PC regimen can get more significant effects and less adverse reactions, so it is worthy to be popularized in clinic.